Health Canada has approved a drug from Roche (ROG: SIX) as a monotherapy for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Alecensaro (alectinib), which is marketed as Alecensa outside Canada, has been approved based on results from the Phase III ALEX study showing that it reduced the risk of disease progression or death by more than half compared to crizotinib, the current standard of care.
Study data also showed that, compared to crizotinib, the Roche treatment reduced the risk of tumors spreading to, or growing in, the brain or CNS by 84%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze